Terms: = Pancreatic cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
6 results:
1. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
[TBL] [Abstract] [Full Text] [Related]
2. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression.
Cheng CS; Tan HY; Wang N; Chen L; Meng Z; Chen Z; Feng Y
Clin Transl Med; 2021 Jun; 11(6):e467. PubMed ID: 34185423
[TBL] [Abstract] [Full Text] [Related]
3. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract] [Full Text] [Related]
4. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
5. Biomarkers in neuroendocrine tumors.
Duque M; Modlin IM; Gupta A; Saif MW
JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
[TBL] [Abstract] [Full Text] [Related]
6. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract] [Full Text] [Related]
